Fischer Medical Ventures Ltd
Fischer Medical Ventures Ltd, earlier known as
Fischer Chemic Ltd, leads a healthcare-technology group. It makes and services medical-imaging equipment and provides
AI-based health screening and digital-health solutions. Its MRI manufacturing plant is located at Andhra Pradesh MedTech Zone (AMTZ), Visakhapatnam.[1]
- Market Cap ₹ 2,396 Cr.
- Current Price ₹ 34.3
- High / Low ₹ 122 / 31.0
- Stock P/E
- Book Value ₹ 5.17
- Dividend Yield 0.15 %
- ROCE -1.58 %
- ROE -3.09 %
- Face Value ₹ 1.00
Pros
- Promoter holding has increased by 0.94% over last quarter.
Cons
- Stock is trading at 6.64 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -1.60% over last 3 years.
- Company has high debtors of 435 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Equipment & Supplies Medical Equipment & Supplies
Part of BSE Healthcare BSE 1000
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | -0 | -0 | 0 | 0 | 0 | 0 | 12 | 5 | 17 | 14 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 7 | 26 | 25 | |
| Operating Profit | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | 0 | -0 | -2 | -9 | -11 |
| OPM % | -300% | -11% | -12% | 11% | -1.6% | -43% | -50% | -81% | |||||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 3 | 4 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 5 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Profit before tax | 0 | -0 | -0 | 0 | 0 | -0 | -0 | -0 | 0 | 1 | 1 | -11 | -14 |
| Tax % | 0% | 0% | 0% | 0% | 0% | -450% | 20% | 26% | 30% | -1% | |||
| 0 | -0 | -0 | 0 | 0 | -0 | 0 | -0 | -0 | 0 | 1 | -10 | -13 | |
| EPS in Rs | 0.01 | -0.01 | -0.02 | 0.00 | 0.00 | -0.24 | 0.82 | -1.35 | -0.24 | 0.01 | 0.01 | -0.16 | -0.21 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 48% | -3% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 152% |
| 3 Years: | 359% |
| TTM: | 39% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -1585% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 69% |
| 5 Years: | 22% |
| 3 Years: | 73% |
| 1 Year: | -70% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -2% |
| Last Year: | -3% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 3 | 3 | 0.17 | 0.17 | 0.17 | 0.17 | 0.17 | 0.17 | 54 | 64 | 65 |
| Reserves | -3 | -3 | -4 | -0 | -0 | -0 | -0 | -0 | -0 | 26 | 272 | 273 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 22 | 46 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 1 | 5 | |
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 92 | 358 | 389 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 11 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 41 | 291 | 304 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 51 | 67 | 74 | |
| Total Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 92 | 358 | 389 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | -0 | -0 | -0 | 0 | 0 | -0 | -0 | -0 | 0 | -23 | -3 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -38 | -232 | -13 | |
| -0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 38 | 255 | 17 | |
| Net Cash Flow | 0 | -0 | 0 | 0 | -0 | 0 | -0 | -0 | 0 | -0 | 0 | 1 |
| Free Cash Flow | 0 | -0 | -0 | -0 | 0 | 0 | -0 | -0 | -0 | 0 | -23 | -3 |
| CFO/OP | -33% | 42% | 50% | 0% | 0% | -100% | 300% | 95% | -750% | -68% | 1,004% | 29% |
Ratios
Standalone / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0 | 0 | 0 | 0 | 0 | 345 | 402 | 1,194 | 435 | |||
| Inventory Days | 0 | 0 | 0 | 6 | 13 | |||||||
| Days Payable | 31 | 114 | ||||||||||
| Cash Conversion Cycle | 0 | 0 | 0 | 0 | 0 | 345 | 402 | 1,169 | 333 | |||
| Working Capital Days | -365 | 365 | 365 | -41 | 21 | -831 | 1,215 | 1,408 | 348 | |||
| ROCE % | -350% | 0% | 8% | -22% | -13% | -97% | 9% | 1% | 0% | -2% |
Insights
In beta| Mar 2024 | Mar 2025 | |
|---|---|---|
| International markets served countries |
|
|
| Total employees employees |
||
| Cumulative preventive health screenings delivered screenings |
||
| MOUs signed for PICA MRI systems at RSNA 2024 MOUs |
||
| MRI manufacturing capacity (double shift maximum) MRI machines per year |
||
| MRI manufacturing capacity (single shift) MRI machines per year |
||
| Schools in health screening partnership schools |
||
| Target annual preventive health screenings screenings per year |
||
| TB and cancer screenings in Assam individuals screened |
||
Extracted by Screener AI
Documents
Announcements
-
Reg. 34 (1) Annual Report.
- Company issued corrigendum and revised FY2025-26 annual report before 33rd AGM.
- Closure of Trading Window
-
Board Meeting Outcome for Board''s Approval For Proposed Investments In Material Wholly Owned Subsidiaries
- Board approved ₹50 crore investment in rights issues of three wholly owned subsidiaries on 24 Sept 2026.
- Presentation Of Investor/Analyst Meeting
-
Chairman''s Message
- Chairman’s letter reviews global expansion, new products, Vecura collaboration, and ₹59.67 crore promoter infill.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Concalls
-
Sep 2026PPT
-
Sep 2026PPT
-
Nov 2025Transcript PPT
-
Dec 2024PPT
Business Transformation
The company has changed from its chemicals business to medical equipment, health screening, and digital-health services.[1]